We thank the reviewer for these questions. Preliminary tests using CD31 staining revealed no differences between the groups regarding blood vessel density and therefore we did not pursue the research in that direction. We agree that measuring the effect of TTFields on the anti-angiogenic effect of sorafenib and on resistance to sorafenib are interesting, these topics were however not within the scope of the current study, and remain for future investigations. Regarding possible discrepancy between the volume fold change and tumor weight, please see below a graph showing tumor volume (as measured by MRI) versus tumor weight, both measured at the end of the study. The graph shows very good correlation between the two parameters, indicating the reliability of the measurements. If the reviewer feels there is discrepancy, it may be due to the volume shown as fold change relative to the initial tumor volume and not as the end value.
Kaplan-Meyer survival curves are mandatory when toxic treatments are combined and compared.